[TheDevs]

Low-Priced Stocks Under $10 with Potential Catalysts: Altimmune, Recursion Pharmaceuticals, and EVgo

Low-priced stocks under $10 have the potential to yield significant returns if the right catalysts align. Several stocks have experienced explosive growth due to favorable market conditions and industry trends. Notable examples include Advanced Micro Devices (AMD), Netflix (NFLX), and Viking Therapeutics (VKTX). In this article, we highlight three stocks under $10 that could present promising investment opportunities: Altimmune (ALT), Recursion Pharmaceuticals (RXRX), and EVgo (EVGO).

Altimmune (ALT), currently trading at $6.40, stands to benefit from the potential $130 billion weight loss drug treatment boom. The company’s unique approach to weight loss treatment, which focuses on preserving lean mass, sets it apart from competitors. Data from a 48-week trial showed that ALT’s treatment resulted in 74.5% weight loss from fat tissue and 25.5% from lean mass. This preservation of lean mass is crucial to avoid severe medical outcomes associated with excessive lean mass loss. Analysts have rated ALT as a strong buy, with an average price target of $23.20 and a highest target of $35.

Recursion Pharmaceuticals (RXRX), priced at $9.30, holds immense potential in the field of drug discovery driven by artificial intelligence (AI). The company has received a $50 million investment from Nvidia (NVDA) to advance its AI-driven drug discovery efforts. Traditional drug discovery is a lengthy and expensive process with a high failure rate. However, AI has the potential to significantly reduce the time and cost involved. Recursion Pharmaceuticals aims to shorten the drug development timeline from 10-15 years and billions of dollars to just 1-2 years and $10-20 million. This innovative approach positions RXRX as a promising player in the industry.

EVgo (EVGO), currently trading at an affordable price, could experience substantial growth in the coming years as the electric vehicle (EV) market expands. The need for an extensive charging infrastructure is a significant challenge for EV adoption. However, automakers are on track for substantial growth, and the installation of more EV charging stations will be a crucial catalyst for companies like EVGO. The company’s business model of owning and operating a fast-charging network has demonstrated strength and achieved record results. EVGO aims to achieve adjusted EBITDA breakeven in 2025, driven by the tailwind of long-term EV adoption.